Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease

Optimising patient outcomes with adjuvant Osimertinib: Improving patient identification through non-smoking related NSCLC screening and EGFR reflex testing

Date

19 Sep 2021

Session

AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease

Presenters

Fan Yang

Authors

F. Yang

Author affiliations

  • Thoracic Surgery, Peking University People’s Hospital, 100044 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction and welcome

Presenter: Egbert F. Smit

Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease

Resources:

Webcast

Meeting close

Presenter: Egbert F. Smit

Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.